Clinical value of miR-198-5p in lung squamous cell carcinoma assessed using microarray and RT-qPCR

Liang, Yue-Ya; Huang, Jiacheng; Tang, Rongjiang; Chen, Wenjie; Chen, Peng; Cen, Wei-Luan; Shi, Ke; Li, Gao; Gao, Xiang; Liu, An‐Gui; Peng, Xuebiao; Huang, Su-Hua; Fang, Ye‐Ying; Gu, Yutong

doi:10.1186/s12957-018-1320-y

Cited by 16 publications

(13 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Otherwise, a random-effects model was applied (I 2 >50%) ( 45 ); meanwhile, heterogeneity analysis was performed to discover the sources of heterogeneity. Subsequently, a summary (s)ROC was created to indicate the ability of miR-193a-3p to identify TC compared with a normal sample ( 46 – 48 ).…”

Section: Methodsmentioning

confidence: 99%

Downregulation of miR‑193a‑3p via targeting cyclin D1 in thyroid cancer

Wen

et al. 2020

Mol Med Rep

View full text Add to dashboard Cite

Thyroid cancer (Tc) is a frequently occurring malignant tumor with a rising steadily incidence. microrna (mirna/mir)-193a-3p is an mirna that is associated with tumors, playing a crucial role in the genesis and progression of various cancers. However, the expression levels of mir-193a-3p and its molecular mechanisms in Tc remain to be elucidated. The present study aimed to probe the expression of miR-193a-3p and its clinical significance in TC, including its underlying molecular mechanisms. Microarray and rna sequencing data gathered from three major databases, specifically Gene expression omnibus (Geo), arrayexpress and The cancer Genome atlas (TcGa) databases, and the relevant data from the literature were used to examine mir-193a-3p expression. Meta-analysis was also conducted to evaluate the association between clinicopathological parameters and mir-193a-3p in 510 Tc and 59 normal samples from the TcGa database. mirWalk 3.0, and the TcGa and Geo databases were used to predict the candidate target genes of mir-193a-3p. Gene ontology, Kyoto encyclopedia of Genes and Genomes and protein-protein interaction network enrichment analyses were conducted by using the predicted candidate target genes to investigate the underlying carcinogenic mechanisms. a dual luciferase assay was performed to validate the targeting regulatory association between the most important hub gene cyclin d1 (ccnd1) and mir-193a-3p. mir-193a-3p expression was considerably downregulated in Tc compared with in the non-cancer controls (P<0.001). The area under the curve of the summary receiver operating characteristic was 0.80. Downregulation of miR-193a-3p was also significantly associated with age, sex and metastasis (P=0.020, 0.044 and 0.048, respectively). Bioinformatics analysis indicated that a low mir-193a-3p expression may augment ccnd1 expression to affect the biological processes of Tc. in addition, ccnd1, as a straightforward target, was validated through a dual luciferase assay. mir-193a-3p and ccnd1 may serve as prognostic biomarkers of Tc. Finally, mir-193a-3p may possess a crucial role in the genesis and progression of Tc by altering the ccnd1 expression.

show abstract

Section: Methodsmentioning

confidence: 99%

Downregulation of miR‑193a‑3p via targeting cyclin D1 in thyroid cancer

Wen

et al. 2020

Mol Med Rep

View full text Add to dashboard Cite

show abstract

“…In a previous study, decreased expression of miR-198-5p was observed in lung squamous cell carcinoma tissues (SMD, −0.34; 95% CI, −0.71–0.04) (49). For LUAD, miR-198-5p initially received attention due to its differential expression between benign pleural effusion and LUAD-associated malignant pleural effusion (LA-MPE).…”

Section: Discussionmentioning

confidence: 95%

Clinical value of microRNA‑198‑5p downregulation in lung adenocarcinoma and its potential pathways

et al. 2019

Self Cite

View full text Add to dashboard Cite

Lung adenocarcinoma (LUAD), the main subtype of non-small cell lung cancer, is known to be regulated by various microRNAs (miRs/miRNAs); however, the role of miR-198-5p in LUAD has not been clarified. In the present study, the clinical value of miR-198-5p in LUAD and its potential molecular mechanism was evaluated. miR-198-5p expression was examined by reverse transcription-quantitative PCR (RT-qPCR) in 101 paired LUAD and adjacent normal lung tissues. Subsequently, the miR-198-5p expression level was determined from microarray data from the Gene Expression Omnibus, ArrayExpress and by meta-analyses. Furthermore, the target mRNAs of miR-198-5p from 12 miRNA-mRNA predictive tools were intersected with The Cancer Genome Atlas (TCGA)-based differentially expressed genes. In addition, Gene Ontology annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were conducted to determine the possible mechanism of miR-198-5p in LUAD. The Search Tool for the Retrieval of Interacting Genes/Proteins database was employed to construct a protein-protein interaction network among the potential target genes of miR-198-5p. The results showed that miR-198-5p expression was lower in LUAD tissues than in adjacent non-cancerous lung tissues (4.469±2.495 vs. 5.301±2.502; P=0.015). Meta-analyses, including the data from the present study and online microarray data, also verified the downregulation of miR-198-5p in 584 cases of LUAD. The expression of miR-198-5p was associated with the age, blood vessel invasion, Tumor-Node-Metastasis stage, and lymph node metastasis of patients with LUAD and served as an independent prognostic factor for survival. The hub genes of miR-198-5p were upregulated in LUAD, according to TCGA and The Human Protein Atlas. For the KEGG pathway analysis, the most enriched KEGG pathway was the p53 signaling pathway (P=1.42×10 −6 ). These findings indicated that the downregulation of miR-198-5p may play a pivotal role in the development of LUAD by targeting various signaling pathways.

show abstract

“…Diagnostic odds ratio, as well as negative and positive likelihood ratios, were also analyzed. In addition, the present study performed sROC analysis to further appraise the distinguishing ability of miR-132-3p (26–28). Thirdly, a Kaplan-Meier analysis was conducted to reveal the prognostic ability of miR-132-3p in CCA based on TCGA data, and a log-rank test was performed to compare the survival between high and low miR-132-3p expression groups.…”

Section: Methodsmentioning

confidence: 99%

Upregulation of miR‑132‑3p in cholangiocarcinoma tissues: A study based on RT‑qPCR, The Cancer Genome Atlas miRNA sequencing, Gene Expression Omnibus microarray data and bioinformatics analyses

Xia

Liu

et al. 2019

Mol Med Report

View full text Add to dashboard Cite

MicroRNAs (miRNAs/miRs) have been reported to be closely associated with numerous human diseases, including cholangiocarcinoma (CCA). However, the number of miRNAs known to be involved in CCA is limited, and the association between miR-132-3p and CCA remains unknown. In the present study, the clinical role of miR-132-3p and its potential signaling pathways were investigated by multiple approaches. Reverse transcription-quantitative PCR (RT-qPCR), CCA-associated Gene Expression Omnibus (GEO), ArrayExpress and Sequence Read Archive (SRA) miRNA-microarray or miRNA-sequencing data were screened, and meta-analyses were conducted, in order to calculate the receiver operating characteristic (ROC) curve and standardized mean difference (SMD). The predicted target genes of miR-132-3p were obtained from 12 online databases and were combined with the downregulated differentially expressed genes identified in the RNA-sequencing data of CCA. Gene Ontology annotation and pathway analysis were performed in WebGestalt. Protein-protein interaction analyses were conducted in STRING. The Cancer Genome Atlas (TCGA) mRNA expression profiles were used to validate the expression levels of hub genes at the mRNA level. The Human Protein Atlas was used to identify the protein expression levels of hub genes in CCA tissues and non-tumor biliary epithelium. The meta-analyses comprised 10 groups of RT-qPCR data, eight GEO microarray datasets and one TCGA miRNA-sequencing dataset. The SMD of miR-132-3p in CCA was 0.75 (95% CI: 0.25, 1.24), which indicated that miR-132-3p was overexpressed in CCA tissues. This finding was supported by a summary ROC value of 0.80 (95% CI: 0.76, 0.83). The pooled sensitivity and specificity were 0.81 (95% CI: 0.59, 0.93) and 0.71 (95% CI: 0.58, 0.81), respectively. The relative expression level of miR-132-3p in the early stage of CCA (stages I–II) was 6.8754±0.5279, which was markedly lower than that in the advanced stage (stages III–IVB), 7.3034±0.3267 (P=0.003). Consistently, the miR-132-3p level in low-grade CCA (grades G1-G2) was 6.7581±0.5297, whereas it was 7.1191±0.4651 in patients with high-grade CCA (grades G3-G4) (P=0.037). Furthermore, 555 potential target genes of miR-132-3p in CCA were mainly enriched in the ‘Focal Adhesion-PI3K-Akt-mTOR-signaling pathway’. In conclusion, upregulation of miR-132-3p may serve a pivotal role in the tumorigenesis and progression of CCA by targeting different pathways. Further in vitro and in vivo studies are required to support the current findings.

show abstract

Clinical value of miR-198-5p in lung squamous cell carcinoma assessed using microarray and RT-qPCR

Cited by 16 publications

References 40 publications

Downregulation of miR‑193a‑3p via targeting cyclin D1 in thyroid cancer

Downregulation of miR‑193a‑3p via targeting cyclin D1 in thyroid cancer

Clinical value of microRNA‑198‑5p downregulation in lung adenocarcinoma and its potential pathways

Upregulation of miR‑132‑3p in cholangiocarcinoma tissues: A study based on RT‑qPCR, The Cancer Genome Atlas miRNA sequencing, Gene Expression Omnibus microarray data and bioinformatics analyses

Contact Info

Product

Resources

About